共 50 条
- [21] Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro- oesophageal junction adenocarcinoma (SPOTLIGHT) : a multicentre, randomised, double-blind, phase 3 trialLANCET, 2023, 401 (10389): : 1655 - 1668Shitara, KoheiLordick, FlorianBang, Yung-JueEnzinger, PeterIlson, DavidShah, Manish A.Van Cutsem, EricXu, Rui-HuaAprile, GiuseppeXu, JianmingChao, JosephPazo-Cid, RobertoKang, Yoon-KooYang, JianningMoran, DiarmuidBhattacharya, PranobArozullah, AhsanPark, Jung WookOh, MokAjani, Jaffer A.
- [22] GLOW: Zolbetuximab plus CAPOX compared with placebo plus CAPOX as first-line treatment for patients with Claudin18.2+/HER2-Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III studyANNALS OF ONCOLOGY, 2019, 30Xu, R-H.Dongsheng, Z.Ajani, J.Al-Batran, S-E.Bang, Y-J.Catenacci, D.Enzinger, P.Ilson, D.Kim, S.Lordick, F.Shitara, K.Van Cutsem, E.Arozullah, A.Park, J. WookShah, M.
- [23] Asian-ethnicity related differences among patients with metastatic gastroesophageal junction (GEJ) and gastric adenocarcinomaANNALS OF ONCOLOGY, 2020, 31 : S917 - S917Honorio, M. X.Suzuki, C.Espin-Garcia, O.Allen, M. J.Ma, L.Almugbel, F. A.Gonzalez, I. LyraDarling, G.Yeung, J. C-W.Chen, E.Kalimuthu, S.Wong, R.Veit-Haibach, P.Jang, R.Elimova, E.
- [24] Prevalence of claudin 18.2 (CLDN18.2) and the association of biomarkers with clinical activity in patients with gastric or gastroesophageal adenocarcinoma (G/GEJa) treated with zolbetuximab.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 466 - 466Moran, Diarmuid MartinGuerrero, AbrahamUeno, YokoPark, Jung WookPavese, JanetKaneko, YuichiroMatsangou, MariaShitara, Kohei
- [25] Zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+(CLDN18.2+) / HER22 locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT studyJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : LBA292 - LBA292Shitara, KoheiLordick, FlorianBang, Yung-JueEnzinger, Peter C.Ilson, David H.Shah, Manish A.Van Cutsem, EricXu, Rui-huaAprile, GiuseppeXu, JianmingChao, JosephPazo-Cid, RobertoKang, Yoon-KooYang, JianningMoran, Diarmuid MartinBhattacharya, Pranob P.Arozullah, AhsanPark, Jung WookAjani, Jaffer A.
- [26] Perioperative sintilimab in combination with concurrent chemoradiotherapy for patients with locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinomaANNALS OF ONCOLOGY, 2020, 31 : S1316 - S1316Wei, J.Lu, X.Liu, Q.Li, L.Liu, S.Liu, F.Fu, Y.Fan, X.Yang, J.Yang, Y.Zhao, Y.Guan, W.Liu, B.
- [27] Comparisons of effects of SOX and mFOLFOX6 chemotherapy regimens on patients with locally advanced gastric cancerJOURNAL OF CHEMOTHERAPY, 2022, 34 (02) : 117 - 122Chen, Gui-DongCao, Bin-XiaoShi, YingLv, Jie-MinWang, Dong-HaiShi, Lun-Bo
- [28] Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma: Updated results from the FAST trial.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)Sahin, UgurTureci, OzlemManikhas, Georgy M.Lordick, FlorianRusyn, AndriyVynnychenko, IhorDudov, AssenBazin, IgorBondarenko, IgorMelichar, BohuslavDhaene, KarlWiechen, KaiMaurus, DanielSchuler, Martin H.Al-Batran, Salah-Eddin
- [29] Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinomaANNALS OF ONCOLOGY, 2023, 34 : S1524 - S1525Ajani, J. A.Lordick, F.Bang, Y-J.Enzinger, P. C.Ilson, D. H.Shah, M. A.van Cutsem, E.Xu, R-H.Aprile, G.Xu, J.Pazo Cid, R. A.Kang, Y-K.Yang, J.Moran, D.Bhattacharya, P.Matsangou, M.Arozullah, A.Park, J. W.Shitara, K.
- [30] Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinomaANNALS OF ONCOLOGY, 2023, 34 : S1322 - S1322Ajani, J. A.Lordick, F.Bang, Y-J.Enzinger, P. C.Ilson, D. H.Shah, M. A.Van Cutsem, E.Xu, R-H.Aprile, G.Xu, J.Cid, R. A. PazoKang, Y-K.Yang, J.Moran, D.Bhattacharya, P.Matsangou, M.Arozullah, A.Park, J. W.Shitara, K.